The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Neomile Growth Fund - Series I
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.7 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Neomile Growth Fund - Series I (a non-promoter entity, likely a foreign/AIF fund managed by Neomile Asset Managers) sold 4,07,255 equity shares of Anlon Healthcare Ltd (0.76% of total share capital) through open market transactions between 8th March 2026 and 10th March 2026. As a result, the fund's holding in the company declined from 27,45,296 shares (5.16%) to 23,38,041 shares (4.40%). This is a routine SAST disclosure triggered because the fund's holding crossed below the 5% threshold as a result of the sale.
The fund reduced its stake below the 5% mark, which may be interpreted as a mild negative signal indicating reduced institutional conviction. However, since the entity is not a promoter and the sale was relatively small, the impact on share price is likely limited. Retail investors should watch for further disclosures to see if this trend continues.